Harmony Biosciences Holdings
HRMY on Nasdaq. Harmony Biosciences sells narcolepsy medicine to patients with sleep disorders. Market value $2.4bn.
Ranked 53 of 1,305 on tonight’s list. On the list every night since 3 August 2026.
For every $100 of what the whole company costs, it produced $14.39 of spare cash last year. A savings account pays about 4.
You pay 8.7 years of operating profit for the business. The average large US company costs around 18.
Each dollar kept in the business earns 18 cents a year. Above 10 is good.
Five years of cash, in billions
| Revenue | $305m | $438m | $582m | $715m | $868m |
| Operating margin | 28.7% | 27.4% | 33.0% | 26.7% | 24.0% |
| Debt to equity | 1.02 | 0.47 | 0.38 | 0.25 | 0.17 |
| Shares outstanding | 0.06bn | 0.06bn | 0.06bn | 0.06bn | 0.06bn |
Health checks
- Free cash flow positive5 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)6 of 9
- Profit backed by cash (accruals)No
- Debt0.17× equity
- Revenue growth, five yearsStrong, 29.9% a year
- Buying back its own sharesRoughly flat
Dates
Funds that own it
None of the funds we track holds it.
Insiders
We do not track insider filings for this company yet.
What could go wrong
Cheap for a reason is the question the numbers cannot answer. Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; the five-year figures are rounded.